Cytomyx Holdings PLC (CYX.L) Acquires Goodwill And Certain Assets From Cytocell Ltd.
10/19/2005 5:10:44 PM
Cytocell Ltd is pleased to announce that Cytomyx Holdings plc (www.cytomyx.com) has acquired the goodwill and certain assets employed in the development, manufacture and sale of kits utilising DNA Probe Technology. The Cytocell product range, which is based on Fluorescence In Situ Hybridisation (FISH) technology, is used for the analysis of chromosomal abnormalities linked to certain genetic disorders.
Cytomyx is a leading provider of a wide range of products and services that support and enhance early stage drug discovery efforts within the pharmaceutical industry. The acquisition is a mutually beneficial relationship whereby Cytomyx increases its activities in the Life Sciences market and enables the new company; Cytocell Technologies Ltd to further enhance its FISH technology and product portfolio.
The acquisition by Cytomyx will allow Cytocell Technologies to develop its existing product line and introduce new innovative probe technology utilising many of the scientific resources from within Cytomyx.
comments powered by